Tenofovir-induced severe hepatitis in occult hepatitis B reactivation.
Department of Medicine, Carmel Medical Center, Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel. Electronic address: gshabib@gmail.com.
George
G
Habib
Department of Pathology, Carmel Medical Center, Haifa, Israel.
Munir
M
Nashashibi
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006509:Hepatitis B / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects; D008111:Liver Function Tests; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D000068698:Tenofovir / Q000009:adverse effects* / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use; D014775:Virus Activation
D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D000068698:Tenofovir; D011241:Prednisone